BriaCell Therapeutics Corp.
| NASDAQ: BCTX |
| Healthcare / Biotechnology / Canada |
| 6.23 | +0.6200 | +11.05% | Vol 1.16M | 1Y Perf -5.56% |
| Jun 24th, 2022 16:00 DELAYED |
| BID | 6.23 | ASK | 6.30 | ||
| Open | 5.67 | Previous Close | 5.61 | ||
| Pre-Market | - | After-Market | 6.17 | ||
| - - | -0.06 -0.96% |
| Target Price | 20.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 221.03 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 25.80 | Earnings Rating | — | |
| Market Cap | 95.19M | Earnings Date | 5th Jul 2022 | |
| Alpha | 9.78 | Standard Deviation | 72.13 | |
| Beta | -48.54 |
Today's Price Range 5.676.38 | 52W Range 4.0612.47 | 5 Year PE Ratio Range -3.50-1.10 |
Summary:
Buy
| Technical Indicators: | Buy |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 11.45% | ||
| 1 Month | 28.72% | ||
| 3 Months | -35.24% | ||
| 6 Months | -33.01% | ||
| 1 Year | -5.56% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -42.39 | |||
ROE last 12 Months | -44.52 | |||
ROA (5Y Avg) | -6.26 | |||
ROA last 12 Months | -41.48 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -46.77 | |||
Return on invested Capital Q | -10.43 | |||
Return on invested Capital Y | -1.43 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -3.10 | ||||
| 1.95 | ||||
| - | ||||
| - | ||||
| -8.10 | ||||
| -0.98 | ||||
| 1.96 | ||||
| 2.95 | ||||
| 33.30M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 121.60 | ||||
| 126.20 | ||||
| 0.00 | ||||
| 0.00 | ||||
| 180.70 | ||||
| Leverage Ratio | 1.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2022 | -0.19 | -0.32 | -68.42 |
| Q02 2022 | -0.17 | -0.24 | -41.18 |
| Q04 2020 | - | -0.58 | - |
| Q02 2020 | - | -1.99 | - |
| Q03 2019 | - | -0.01 | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 5th Jul 2022 |
| Estimated EPS Next Report | -0.19 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 1.16M |
| Shares Outstanding | 15.28K |
| Shares Float | 15.52M |
| Trades Count | 7.48K |
| Dollar Volume | 7.07M |
| Avg. Volume | 546.95K |
| Avg. Weekly Volume | 382.19K |
| Avg. Monthly Volume | 409.30K |
| Avg. Quarterly Volume | 849.36K |
BriaCell Therapeutics Corp. (NASDAQ: BCTX) stock closed at 6.23 per share at the end of the most recent trading day (a 11.05% change compared to the prior day closing price) with a volume of 1.16M shares and market capitalization of 95.19M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 0 people. BriaCell Therapeutics Corp. CEO is William Williams.
The one-year performance of BriaCell Therapeutics Corp. stock is -5.56%, while year-to-date (YTD) performance is -24.76%. BCTX stock has a five-year performance of %. Its 52-week range is between 4.06 and 12.47, which gives BCTX stock a 52-week price range ratio of 25.80%
BriaCell Therapeutics Corp. currently has a PE ratio of -3.10, a price-to-book (PB) ratio of 1.95, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -41.48%, a ROC of -46.77% and a ROE of -44.52%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from BriaCell Therapeutics Corp., there were 0 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.19 for the next earnings report. BriaCell Therapeutics Corp.’s next earnings report date is 05th Jul 2022.
The consensus rating of Wall Street analysts for BriaCell Therapeutics Corp. is Strong Buy (1), with a target price of $20, which is +221.03% compared to the current price. The earnings rating for BriaCell Therapeutics Corp. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BriaCell Therapeutics Corp. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BriaCell Therapeutics Corp. has a Buy technical analysis rating based on Technical Indicators (ADX : 49.69, ATR14 : 0.57, CCI20 : 91.33, Chaikin Money Flow : 0.07, MACD : 0.01, Money Flow Index : 62.28, ROC : 1.96, RSI : 56.26, STOCH (14,3) : 65.03, STOCH RSI : 0.78, UO : 46.92, Williams %R : -34.97), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BriaCell Therapeutics Corp. in the last 12-months were:
BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte drugs, INCMGA00012, and epacadostat, in advanced breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing and is designed to produce a potent and selective immune response against the cancer of each patient eliminating the time, expense and complex manufacturing logistics associated with immunotherapies.
CEO: William Williams
Telephone: +1 604 921-1810
Address: 235 - 15th Street, Vancouver V7T 2X1, BC, CA
Number of employees: 0
